Background: The increase in portal vascular resistance is a significant complication of metastatic disease to the liver or locally advanced cancer, e.g., biliary cancer.
History and treatment

Casel
A 59-year-old female patient was diagnosed with breast cancer (T 2 NiMo) in 1982, and was treated by modified radical mastectomy and axillary dissection, followed by an adjuvant chemotherapy with cyclophosphamide, methotrexate, fluorouracil (CMF), and antiestrogen therapy with tamoxifen from 1985 until 1990. In 1990, the patient was found to have liver metastases. The patient was treated with various chemotherapy-regimen (NOSTE, trophosphamide, paclitaxel), but since 1993 the liver metastases slowly progressed. In November 1995, the patient was admitted to our emergency unit with an acute gastrointestinal bleeding. Endoscopy revealed hemorrhagic gastritis and esophageal varices grade I. Duplex-ultrasonography demonstrated portal hypertension due to the compression of the large hepatic veins by metastases, functionally resembling a hepatic outflow obstruction (Budd-Chiari syndrome). In December 1995, the patient had a second episode of acute, severe gastrointestinal bleeding. Endoscopy displayed an acute bleeding from a gastric varices and grade III esophageal varices. This and the presence of severe ascites led us to consider the TIPS procedure as a palliative treatment. The rationale for this was to decompress the hepatic venous congestion by creating a side to side porto-caval shunt (Figure la) . Two days after the acute bleeding, the TIPS procedure was performed as described earlier [1] , establishing a DA-CRON® covered Cragg-stent (Min-Tec, Elsenfeld, Germany) to inhibit the ingroth of the tumor into the stent lumen. The decompressive effect of the shunt was substantial, decreasing the pressure-gradient from 39 cm H 2 O Figure I . a) The transjugular transhepatic stent-shunt technique (TIPS) in malignant portal hypertension due to hepatic outflow obstruction (case 1). b) The transjugular transhepatic access (TIPS technique) for the stent placement in malignant prehepatic portal vein obstruction (case 2).
to 11 cm H 2 0. The performance status of the patient significantly improved (Karnofsky-index pre-treatment: 50%, after treatment: 70%), allowing an early ambulation after the TIPS procedure. During follow-up examinations, shunt patency was confirmed, the ascites resolved, and the patient was discharged after a first cycle of an epirubicin-chemotherapy 11 days after the TIPS procedure. Since then, the patient has been seen for further epirubicin cycles. She has a constant elevation of her performance status, no signs of rebleeding, shunt insufficiency, liver dysfunction or hepatic encephalopathy, and no pulmonary metastases.
Case 2
A 49-year-old woman with the diagnosis of proximal bile duct carcinoma, established in May 1993, was treated initially by resection of the left lobe of the liver. In November 1994, the patient had a local tumor recurrence with intrahepatic cholestasis, and peripancreatic and paraaortal lymph node metastases, suggesting inoperability. A four week combined modality treatment with 5-fluorouracil, cisplatin and fractionated radiation therapy was started in December 1994 and repeated in March/April 1995 with a good subjective and objective response. In July 1995, the patient presented with a malignant obstruction of the distal common bile duct. After endoscopic placement of an endoprosthesis into the bile duct, the obstructive symptoms resolved. Eight weeks later, the patient was readmitted with severe abdominal pain, ascites and dilated abdominal veins (caput medusae). Duplex-sonography displayed a severe stenosis of the portal vein with an estimated pressure-gradient > 25 cm H 2 O, leading to severe mesenteric congestion. Even though cytological examination of the ascites revealed tumor cells, low protein and cholesterol concentrations suggested the portal genesis as the main cause of the ascites.
The transjugular transhepatic access to the portal vein (TIPS technique) was used for the placement of two Palmaz-stents (Johnson & Johnson, Hamburg, Germany) in order to treat the intestinal congestion and the tense ascites (Figure lb) . The 4 cm portal vein stenosis ( Figure  2a) was bridged by the dilatation of the stents to a diameter of 14 mm, decreasing the pressure gradient from 27 cm H 2 O to 0 cm H 2 O, and restoring the normal portal perfusion of the liver (Figure 2b ). The abdominal pain substantially improved directly after stent implantation and the ascites was absorbed within 2 weeks. This was accompanied by a significant improvement of the patients performance status (Karnofsky-index pre-treatment: 40%, after treatment: 60%). A follow-up duplexexamination 4 days after the stent placement demonstrated an excellent stent function. Five days after the TIPS procedure, the patient was discharged home. Follow-up examinations confirmed the stent patency and only minimal residual ascites in the abdominal pouches, until the patient died 3 months after the stent implantation due to progression of the biliary cancer and cancer cachexia. 
Discussion
The cases reported herein demonstrate the feasibility and efficacy of the transjugular intrahepatic portosystemic stent-shunt (TIPS) technique in malignant portal hypertension. Since its introduction in 1988, this technique has been used for the implantation of stents bridging the liver tissue between the portal and the hepatic veins with impressive results in patients with variceal hemorrhage due to cirrhosis [1] , patients with refractory ascites [2] and Budd-Chiari syndrome [3] .
Portal hypertension may be an important complication of liver metastases or locally advanced cancer, e.g. biliary or hepatocellular cancer, leading to ascites, portal vein thrombosis, mesenteric ischemia, and live-threatening gastrointestinal bleeding. In these cases, patients may suffer more from symptoms associated with portal hypertension, rather than from systemic effects of disseminated cancer, leading to a serious reduction in the patients performance status.
The percutaneous transhepatic access for the placement of extendable stents into the portal vein in cancer patients has been described in case reports [i.e., 41. The transjugular intrahepatic portocaval shunt (TIPS) and hepatic vein-to-caval stenting in a patient with hepatic metastases and portal hypertension has been reported recently by Davies et al. [5] . In contrast to their observation, the intervention was associated in our patients with a rapid and significant improvement in the patients performance status, no detectable side effects, and a lasting shunt function with a follow-up of 4 (patient 1) and 3 months (patient 2).
This paper also describes the first case of portal hypertension due to malignant prehepatic portal vein obstruction treated successfully by the transjugular placement of a stent into the portal vein (case 2).
A possible risk of the TIPS procedure is to accelerate the dissemination of malignant cells which might be mobilized and spread by the intervention, and the filter function of the liver might partly be abolished. In the first patient, the variceal bleeding required the prompt decision for an intervention, and with the presence of refractory ascites, the decision for a stent-shunt placement seemed to be justified even with multiple liver metastases. Our second patient had a prehepatic portal vein obstruction, so we considered the risk for distant tumor dissemination to be low. Another problem of TIPS is an increased incidence of hepatic encephalopathy after establishing the portosystemic shunt. However, most of the patients with hepatic tumors have well preserved hepatic function and the risk of hepatic encephalopathy may be considerably lower than in patients with liver cirrhosis. In our two patients, no signs of encephalopathy could be detected during follow-up.
In malignant biliary obstruction, percutaneous or endoscopic stenting has become a widely accepted method for palliation with encouraging results [6] . The TIPS technique may become a comparably accepted treatment for malignant portal hypertension.
New treatment modalities like immunotherapy or combined modality treatment may lead to a longer survival of patients with incurable, advanced tumor diseases. Therefore, more patients with liver metastases or locally advanced cancer may suffer from symptoms associated with portal hypertension. In selected patients, the TIPS technique offers an effective and minimal invasive treatment for portal decompression, improving the patient's performance status and allowing a prolonged treatment in an ambulatory setting.
